Structure Therapeutics (GPCR) CFO receives large option and RSU grants

Rhea-AI Filing Summary

Structure Therapeutics Inc. chief financial officer Yoon Jun reported receiving new equity compensation awards. He was granted employee stock options for 128,892 Ordinary Shares at an exercise price of $16.82 per share, expiring on March 18, 2036. One quarter of these options vest on March 1, 2027, with the remainder vesting in 36 monthly installments thereafter.

He also received 104,085 restricted stock units, each representing one Ordinary Share, vesting in four equal annual installments starting on March 1, 2026, subject to continued service. Following these awards, he held 1,401,656 Ordinary Shares directly and 1,554,586 Ordinary Shares indirectly through The Yoon Family Trust. The company’s Ordinary Shares may also be represented by ADSs, with each ADS equal to three Ordinary Shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yoon Jun

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/19/2026		A(2)		104,085	A	$0	1,401,656	D
Ordinary Shares(1)								1,554,586	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$16.82(4)	03/19/2026		A		128,892		(5)	03/18/2036	Ordinary Shares(1)	128,892	$0	128,892	D

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

2. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates.

3. By Jun Sik Yoon and Hayung Yang Yoon, Trustees of The Yoon Family Trust, dated December 11, 2019.

4. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.

5. 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

	/s/ Jun Yoon	03/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Structure Therapeutics (GPCR) CFO Yoon Jun receive?

The CFO received stock options for 128,892 Ordinary Shares at $16.82 per share and 104,085 restricted stock units. These awards are compensation grants, not market purchases, and increase his long-term equity exposure to Structure Therapeutics.

How do the new stock options for GPCR’s CFO vest and when do they expire?

The options begin vesting with 25% on March 1, 2027, then in 36 equal monthly installments thereafter. All options expire on March 18, 2036, aligning the CFO’s incentives with long-term company performance over roughly a ten-year horizon.

What is the vesting schedule for the 104,085 RSUs granted to GPCR’s CFO?

The 104,085 RSUs vest in four equal annual installments starting on March 1, 2026. Each RSU converts into one Ordinary Share upon vesting, provided the CFO continues in service through each annual vesting date.

How many Structure Therapeutics (GPCR) shares does the CFO hold after these grants?

After the grants, the CFO directly held 1,401,656 Ordinary Shares and indirectly held 1,554,586 Ordinary Shares through The Yoon Family Trust. These positions show a substantial ongoing stake alongside the newly awarded options and RSUs.

How are Structure Therapeutics Ordinary Shares related to its ADSs (ticker GPCR)?

Each American Depositary Share (ADS) of Structure Therapeutics represents three Ordinary Shares. This means reported Ordinary Share amounts can be divided by three to understand their equivalent number of ADSs traded on U.S. markets.